Want to see SE:KLAR full AI Analyst Report?

Klaria Pharma Holding AB (KLAR) Price & Analysis

7 Followers

KLAR Stock Chart & Stats

kr0.80

kr0.01(1.75%)

At close: Jul 28 4:00 PM EDT

kr0.80

kr0.01(1.75%)

Day’s Range― - ―

52-Week Rangekr0.45 - kr1.33

Previous CloseN/A

Volume302.65K

Average Volume (3M)951.39K

Market Cap

kr146.36M

Enterprise Valuekr195.31

Total Cash (Recent Filing)kr8.47M

Total Debt (Recent Filing)kr9.70M

Price to Earnings (P/E)―

Beta2.05

Next Earnings

Nov 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.17

Shares Outstanding245,976,150

10 Day Avg. Volume506,547

30 Day Avg. Volume951,394

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)-31.79

Price to Sales (P/S)13.71

P/FCF Ratio-3.52

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.1

Revenue Forecast (FY)kr24.00M

Bulls Say, Bears Say

Bulls Say

Buccal Film PlatformKlaria’s buccal thin-film platform gives the company a defined technological focus within specialty pharmaceuticals. If the delivery approach demonstrates clinical and regulatory value, it could support multiple product programs and create a reusable foundation for future partnering or commercialization.

Multiple Monetization RoutesThe business model offers several potential paths to monetization rather than relying solely on direct product sales. Licensing, milestones, royalties, and collaboration payments could allow Klaria to leverage larger pharmaceutical partners and reduce the need to build a large commercial organization.

2025 Revenue RecoveryThe reported increase in annual revenue during 2025 indicates that the company has demonstrated some ability to generate more commercial or development-related income than in the prior year. Continued improvement could provide a foundation for future scale, although profitability has not yet followed.

Bears Say

Persistent LossesKlaria has not yet converted its development activities into a sustainable earnings model. Minimal trailing revenue alongside substantial recurring losses means operating scale remains far below the level needed to support the business, leaving future progress dependent on successful pipeline advancement and external funding.

Ongoing Cash BurnPersistent negative operating and free cash flow shows that the company is not currently self-funding its operations. Continued cash consumption can constrain research and development progress, increase reliance on financing or partners, and make execution more sensitive to delays in commercialization or licensing.

Negative EquityNegative stockholders’ equity signals a materially weakened capital position and reduces financial flexibility. Even with moderate TTM debt, the balance-sheet deficit can make future financing more difficult or dilutive and raises the risk that additional capital will be needed to sustain development programs.

KLAR FAQ

What was Klaria Pharma Holding AB’s price range in the past 12 months?

Klaria Pharma Holding AB lowest stock price was kr0.45 and its highest was kr1.33 in the past 12 months.

What is Klaria Pharma Holding AB’s market cap?

Klaria Pharma Holding AB’s market cap is kr146.36M.

When is Klaria Pharma Holding AB’s upcoming earnings report date?

Klaria Pharma Holding AB’s upcoming earnings report date is Nov 26, 2026 which is in 66 days.

How were Klaria Pharma Holding AB’s earnings last quarter?

Klaria Pharma Holding AB released its earnings results on Aug 31, 2026. The company reported -kr0.052 earnings per share for the quarter.

Is Klaria Pharma Holding AB overvalued?

According to Wall Street analysts Klaria Pharma Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Klaria Pharma Holding AB pay dividends?

Klaria Pharma Holding AB does not currently pay dividends.

What is Klaria Pharma Holding AB’s EPS estimate?

Klaria Pharma Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Klaria Pharma Holding AB have?

Klaria Pharma Holding AB has 245,976,150 shares outstanding.

What happened to Klaria Pharma Holding AB’s price movement after its last earnings report?

Klaria Pharma Holding AB reported an EPS of -kr0.052 in its last earnings report. Following the earnings report the stock price went down -31.425%.

Which hedge fund is a major shareholder of Klaria Pharma Holding AB?

Currently, no hedge funds are holding shares in SE:KLAR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Klaria Pharma Holding AB

Klaria Pharma Holding AB (publ.) functions as a pharmaceutical enterprise, active both in Sweden and across global territories. Its current portfolio features Sumatriptan for migraine management and Midazolam for combating acute epileptic seizures. Within its pipeline, Klaria is developing Epinephrine/Adrenaline to address severe allergic responses, Naloxone for reversing opioid overdoses, and Ketamine for applications in acute pain and mood disorders. Moreover, the company is actively involved in bringing cannabis/cannabinoid products, including THC and CBD, to market for medical and recreational purposes. Established in 2014, Klaria is headquartered in Uppsala, Sweden.